Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. A. M. Kerstjens, E. Bleecker, E. Meltzer, T. Casale, E. Pizzichini, O. Schmidt, M. Engel, L. J. Bour, C. B. Verkleij, P. M. Moroni-Zentgraf, E. D. Bateman (Groningen, Alkmaar, Netherlands; Winston-Salem, San Diego, Omaha, United States Of America; Santa Catarina, Brazil; Koblenz, Ingelheim am Rhein, Biberach an der Riss, Germany; Cape Town, South Africa). Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety. Eur Respir J 2013; 42: Suppl. 57, 4629

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Tiotropium Respimat® add-on therapy in children with symptomatic asthma Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 LATE-BREAKING ABSTRACT: Once-daily tiotropium Respimat® add-on therapy improves lung function in children with moderate symptomatic asthma Source: International Congress 2016 – Living with asthma around the globe Year: 2016 Bronchodilator responsiveness after ICS treatment Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014